skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

Review

(2687) Views  (1061) Full article downloads

Authors: Rudolph M Navari

Published Date December 2009 Volume 2009:1 Pages 167 - 176
DOI: http://dx.doi.org/10.2147/CMAR.S6460

Rudolph M Navari

Indiana University School of Medicine South Bend, South Bend, IN USA

Abstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickness) are the major risk factors for CINV. This review provides a detailed description of palonosetron, a second-generation 5-hydroxytryptamine 3 (5-HT3) receptor antagonist. The chemistry and pharmacology of palonosetron are described, as well as the initial and recent clinical trials. Palonosetron has a longer half-life and a higher binding affinity than the first-generation 5-HT3 receptor antagonists. Palonosetron has been approved for the prevention of acute CINV in patients receiving either moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV in patients receiving moderately emetogenic chemotherapy. In recent studies, compared to the first-generation 5-HT3 receptor antagonists, palonosetron in combination with dexamethasone demonstrated better control of delayed CINV in patients receiving highly emetogenic chemotherapy. There were no clinically relevant adverse reactions reported in the palonosetron clinical trials which were different from the common reactions reported for the 5-HT3 receptor antagonist class. Due to its efficacy in controlling both acute and delayed CINV, palonosetron may be very effective in the clinical setting of multiple-day chemotherapy and bone marrow transplantation.

Keywords: anti-emetics, chemotherapy-induced nausea and vomiting, serotonin receptor antagonists, palonosetron








Readers of this article also read:

Management of postoperative nausea and vomiting: focus on palonosetron
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Determinants to optimize response to clopidogrel in acute coronary syndrome
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University